Trutakna (atacicept-vymj) coverage for primary immunoglobulin A nephropathy
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0306 alerts
Get alerted when Policy CC-0306 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity review for Trutakna (atacicept-vymj) used to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression. It applies to providers requesting coverage under a member's medical benefit or clinical review process.
New clinical criteria and a quantity limit were added for Trutakna.
HCPCS codes C9399 and J3590 and ICD-10-CM code range N02.B1-N02.B9 were added for Trutakna and recurrent or persistent IgA nephropathy.
Documentation requirements were added for biopsy verification and concurrent background therapy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.